GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chordia Therapeutics Inc (TSE:190A) » Definitions » Retained Earnings

Chordia Therapeutics (TSE:190A) Retained Earnings : 円-6,698.12 Mil (As of Feb. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Chordia Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Chordia Therapeutics's retained earnings for the quarter that ended in Feb. 2025 was 円-6,698.12 Mil.

Chordia Therapeutics's quarterly retained earnings declined from May. 2024 (円-5,072.13 Mil) to Aug. 2024 (円-5,721.78 Mil) and declined from Aug. 2024 (円-5,721.78 Mil) to Feb. 2025 (円-6,698.12 Mil).

Chordia Therapeutics's annual retained earnings increased from Aug. 2022 (円-4,117.99 Mil) to Aug. 2023 (円-3,894.65 Mil) but then declined from Aug. 2023 (円-3,894.65 Mil) to Aug. 2024 (円-5,721.78 Mil).


Chordia Therapeutics Retained Earnings Historical Data

The historical data trend for Chordia Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordia Therapeutics Retained Earnings Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Retained Earnings
-2,338.93 -4,117.99 -3,894.65 -5,721.78

Chordia Therapeutics Quarterly Data
Aug21 Aug22 May23 Aug23 May24 Aug24 Feb25
Retained Earnings Get a 7-Day Free Trial -3,369.82 -3,894.65 -5,072.13 -5,721.78 -6,698.12

Chordia Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Chordia Therapeutics  (TSE:190A) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Chordia Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.

Chordia Therapeutics Headlines

No Headlines